Experience
Avara

Experience Avara

Sep 7, 2018 10:30:00 AM

Avara Pharmaceutical Services Finalizes Acquisition of Major Sterile Manufacturing Facility and Development Center in Canada

by Avara Pharmaceutical Services

Norwalk, CT, September 6, 2018 – Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), today announced that it has closed on the transaction with Sandoz to acquire the largest sterile manufacturing facility for injectable medicines in Canada, as part of a continuing expansion of its global footprint.

Read More [fa icon="long-arrow-right"]
Topics: News

May 30, 2018 3:07:23 PM

Avara Pharmaceutical Services Acquires Major Sterile Manufacturing Facility and Development Center in Canada

by Avara Pharmaceutical Services

Norwalk, CT, May 25, 2018 – Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), today announced that it has agreed to acquire the largest sterile manufacturing facility for injectable medicines in Canada from a leading global pharmaceutical company, as part of a continuing expansion of its global footprint.

Read More [fa icon="long-arrow-right"]
Topics: News

Sep 21, 2017 11:44:39 AM

Avara Pharmaceutical Services acquires Secondary Manufacturing and Packaging facility from GSK in Aiken, South Carolina

by William L. Pasek


Avara Pharmaceutical Services is a world class contract development and manufacturing organization (CDMO) with an extensive network serving the global bio-pharmaceutical market

Avara Pharmaceutical Services has signed an agreement with GSK to acquire a GSK Secondary Manufacturing and Packaging facility in Aiken, South Carolina. "This acquisition is an important component of our strategic plan and expands our services by adding additional solid dose capability in the United States, which is in very high demand," stated Timothy C. Tyson, Chairman and CEO. The transaction is expected to complete on or before June 1, 2018.

Read More [fa icon="long-arrow-right"]
Topics: News

Aug 22, 2017 2:03:16 PM

Avara Pharmaceutical Services acquires Sterile facility from Pfizer in Italy

by William L. Pasek


Avara Pharmaceutical Services is a world class contract development and manufacturing organization (CDMO) with an extensive network serving the global bio-pharmaceutical market

Norwalk, CT, August 2017 -- Avara Pharmaceutical Services has signed an agreement with Pfizer Inc. to acquire the Liscate, Italy sterile manufacturing facility. “This acquisition is an important component of our strategic plan and expands our services by adding sterile processing capability, which is in very high demand”, stated Timothy C. Tyson, Chairman and CEO.

Read More [fa icon="long-arrow-right"]
Topics: News

Sep 19, 2016 8:43:00 AM

Avara Pharmaceutical Services Celebrates One Year Since Launch With Arecibo (PR) Site and Acquisition of Shannon, Ireland Site

by William L. Pasek

 
Created in 2015, Avara Pharmaceutical Services is a state-of-the-art contract development and manufacturing organization (CDMO) providing both primary formulation and manufacturing, and secondary manufacturing and packaging of small molecules.

Read More [fa icon="long-arrow-right"]
Topics: News

Sep 6, 2016 10:46:00 AM

Avara Acquires AstraZeneca UK Manufacturing Facility

by William L. Pasek


Norwalk, CT, September 6, 2016
- Avara Pharmaceutical Services, Inc. (“Avara”) today announced that they have entered into an agreement under which Avara will acquire AstraZeneca’s manufacturing facility located in Avlon, Avonmouth, England.

Read More [fa icon="long-arrow-right"]
Topics: News

Aug 3, 2016 11:02:00 AM

Avara Acquires Astellas U.S. Manufacturing Facility

by William L. Pasek


Norwalk, CT, August 3rd, 2016 –Avara Pharmaceutical Services, Inc. announced that its subsidiary, Avara Norman Pharmaceutical Services, Inc. (“Avara”) entered into an agreement under which Avara will acquire Astellas’s wholly owned manufacturing subsidiary Astellas Pharma Technologies (APT), Inc., located in Norman, Oklahoma. 

Read More [fa icon="long-arrow-right"]
Topics: News